Building a DE&I benefits tool kit
Unlock the potential of DE&I in the modern workplace by reshaping benefits to create loyalty, inclusivity, and specialized support for all employees
Read article
TELUS Health - English
Unlock the potential of DE&I in the modern workplace by reshaping benefits to create loyalty, inclusivity, and specialized support for all employees
Read article
Error - something went wrong!
Receive insights on the latest healthcare trends delivered right to your inbox.
Thank you!
Half of plan members reported that the coverage level of at least one of their health benefits limited their ability to seek treatment...
Read article
Unlock valuable insights into the ever-changing world of private drug plans.
Read article
Relatively new in Canada, cost-effectiveness analysis focuses on identifying therapies that may not be the most economical but that represents good value for money.
Read article
Discover the profound impact of the pandemic on workplace mental health and learn why employers must address it. Here's how employers can help create healthier workplaces to inspire future leaders.
Read article
Industry experts share their insights into how real-world evidence (RWE) can enhance reimbursement decision-making for private drug plans.
Read article
Diabetes, asthma, depression and attention deficit hyperactivity disorder (ADHD)—these categories are driving utilization and spend in private drug plans. Here's what private payors need to know.
Read article
The key drivers of change in spending by private drug plans in 2022 can be boiled down to two words: biosimilars and diabetes.
Read article
Presentations from April 26 and May 3, 2023.
Read article
Employers are leading the way in terms of mental healthcare. But mental health success stories are dependent on early diagnosis and there continues to be significant barriers to access.
Read article
For the 19th consecutive year, TELUS Health is looking forward to welcoming a record number of participants at our upcoming virtual annual conference.
Read article
The slow but steady adoption of biosimilars is big news. With provinces increasingly making the switch to biosimilar medications, the biosimilar wave has started across Canada.
Read article
Developments in the diabetes category—the second largest category by eligible amount in 2022—will have the biggest impact on private plans this year.
Read article
The future of private drug insurance can be friendly, as long as plan sponsors take action in mitigating ever-increasing drug costs through a variety of strategies.
Read article
COVID-19 pushed an industry that was slowly digitizing to move quickly to meet the rapidly evolving needs of its employers and plan members.
Read article
For the second year in a row, fewer claims were made for prescription drugs while the average eligible amounts per insured and per claim increased.
Read article
Mental health indicators are in decline lately, a function of the recent economic downturn and three years of a global pandemic. Many employees are feeling isolated, anxious and unproductive.
Read article
Supporting employee mental health and well-being is clearly the right thing to do – but it’s also a business imperative. That was a key message from the speakers at the “Prescription for a...
Read article
Presentations from May 10 & 17, 2022 events "Retrospective 2021: Data trends and national benchmarks" with Shawn O’Brien, Principal, Data Enablement, TELUS Health
Read article
Is it better for patients to take more of their current medication or start new medication? The challenge is knowing to ask the question in the first place.
Read article
Loading more...